These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 36258237)
21. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension? van Thor MCJ; Ten Klooster L; Snijder RJ; Kelder JC; Mager JJ; Post MC Lung; 2019 Dec; 197(6):753-760. PubMed ID: 31583452 [TBL] [Abstract][Full Text] [Related]
22. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis. Gatfield J; Mueller Grandjean C; Bur D; Bolli MH; Nayler O PLoS One; 2014; 9(9):e107809. PubMed ID: 25226600 [TBL] [Abstract][Full Text] [Related]
23. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials. Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207 [TBL] [Abstract][Full Text] [Related]
24. Macitentan for the treatment of pulmonary arterial hypertension. Sood N Expert Opin Pharmacother; 2014 Dec; 15(18):2733-9. PubMed ID: 25385427 [TBL] [Abstract][Full Text] [Related]
25. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Aversa M; Porter S; Granton J Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028 [TBL] [Abstract][Full Text] [Related]
26. Macitentan in the treatment of pulmonary arterial hypertension. Zebadúa R; Hernández-Pérez AP; García A; Zayas N; Sandoval J; López J; Pulido T Future Cardiol; 2021 Jan; 17(1):49-58. PubMed ID: 32677463 [TBL] [Abstract][Full Text] [Related]
27. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Correale M; Ferraretti A; Monaco I; Grazioli D; Di Biase M; Brunetti ND Vasc Health Risk Manag; 2018; 14():253-264. PubMed ID: 30323613 [TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes. Lepist EI; Gillies H; Smith W; Hao J; Hubert C; St Claire RL; Brouwer KR; Ray AS PLoS One; 2014; 9(1):e87548. PubMed ID: 24498134 [TBL] [Abstract][Full Text] [Related]
31. Prescribing of endothelin receptor antagonists and riociguat in women of childbearing age in a large German claims database study. Amann U; Nadine Wentzell ; Kollhorst B; Haug U Reprod Toxicol; 2023 Aug; 119():108415. PubMed ID: 37245698 [TBL] [Abstract][Full Text] [Related]
32. Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan. Tynan T; Hird K; Hannon T; Gabbay E J Int Med Res; 2019 May; 47(5):2177-2186. PubMed ID: 30975046 [TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran. Ekhlasi M; Sheikhi S; Majd ZK; Peiravian F; Yousefi N Value Health Reg Issues; 2023 Mar; 34():78-85. PubMed ID: 36599206 [TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. Sidharta PN; Krähenbühl S; Dingemanse J Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):437-49. PubMed ID: 25604973 [TBL] [Abstract][Full Text] [Related]
36. Autoimmune hepatitis in a patient with pulmonary arterial hypertension treated with endothelin receptor antagonists. Naito A; Terada J; Tanabe N; Sugiura T; Sakao S; Kanda T; Yokosuka O; Tatsumi K Intern Med; 2014; 53(7):771-5. PubMed ID: 24694495 [TBL] [Abstract][Full Text] [Related]
37. The use of Macitentan in Fontan circulation: a case report. Demetriades P; Aziz A; Condliffe R; Bowater SE; Clift PF BMC Cardiovasc Disord; 2017 May; 17(1):131. PubMed ID: 28532389 [TBL] [Abstract][Full Text] [Related]
38. Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension. Safdar Z; Thakur A; Frost A South Med J; 2017 Mar; 110(3):223-228. PubMed ID: 28257550 [TBL] [Abstract][Full Text] [Related]